Medulloblasoma: Challenges for effective immunotherapy

Adam M. Sonabend*, Alfred T. Ogden, Lisa M. Maier, David E. Anderson, Peter Canoll, Jeffrey N. Bruce, Richard C.E. Anderson

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

For medulloblastoma patients, the current therapeutic paradigm of surgery followed by radiation and chemotherapy can lead to long-term remission. However, the sequelae of treatment can be very debilitating, particularly in young children. Immunotherapy is an attractive treatment approach to optimize the targeting of tumor cells while sparing the vulnerable surrounding brain that is still developing in children. Understanding the relationship between medulloblastoma and the immune system is critical to develop effective immunologic-based treatment strategies for these patients. This review focuses on current knowledge of tumor immunology and the factors that contribute to the lack of immune system recognition of these tumors. The specificity of tumor antigens present in medulloblastoma is also discussed along with a summary of early clinical immunotherapy results.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalJournal of Neuro-Oncology
Volume108
Issue number1
DOIs
StatePublished - May 2012

Keywords

  • Antigen
  • CTA
  • Immunotherapy
  • LAK
  • Lymphocyte
  • Medulloblastoma

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Medulloblasoma: Challenges for effective immunotherapy'. Together they form a unique fingerprint.

Cite this